| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
BTK
PCI-33380 targets Bruton's tyrosine kinase (BTK) with high selectivity and irreversible binding. The compound covalently binds to BTK, forming a stable inhibitor-enzyme complex. Its fluorescent properties, with excitation/emission wavelengths of 532/555 nm, allow for visualization and tracking of BTK in cells and tissues. |
|---|---|
| ln Vitro |
PCI-33380 bound to Btk could be found using fluorescent gel scanning and denaturing gel electrophoresis[2].
In vitro, PCI-33380 specifically binds to BTK protein in B-cell lysates. The fluorescent probe allows for detection of BTK in cellular assays without the need for antibodies or other detection reagents. The compound's activity-based probe design enables the study of BTK occupancy, localization, and dynamics in living cells. |
| ln Vivo |
In vivo, PCI-33380 has been used to study BTK engagement in animal models. The fluorescent probe allows for tracking of BTK inhibition and binding in tissues, providing a direct link between inhibitor binding and biological responses. This makes PCI-33380 a valuable tool for pharmacodynamic studies of BTK inhibitors.
|
| Enzyme Assay |
In vitro binding assays for PCI-33380 involve incubating the fluorescent probe with B-cell lysates or purified BTK protein. The binding of PCI-33380 to BTK is detected by fluorescence polarization or by measuring fluorescence intensity after gel electrophoresis. Competition assays with unlabeled BTK inhibitors are used to confirm specificity.
|
| Cell Assay |
Cell Line: Human B cells.
Concentration: 2 μM. Incubation Time: 1 h. Result: Found that 10 nM of PCI-32765 was sufficient to fully occupy the active site of Btk in primary B cells in culture by using the fluorescently tagged derivative PCI-33380. Cellular assays are performed using B-cell lymphoma cell lines such as Ramos or other BTK-expressing cells. Cells are treated with PCI-33380 at various concentrations, and BTK binding is visualized by fluorescence microscopy or flow cytometry. The compound's ability to label BTK in living cells allows for real-time monitoring of BTK localization and dynamics. |
| Animal Protocol |
In vivo studies are conducted in mouse models of B-cell malignancies. PCI-33380 is administered intravenously or intraperitoneally, and tissues are collected for fluorescence imaging. BTK engagement and inhibition are assessed by measuring fluorescence intensity in tissues, and the correlation between inhibitor binding and biological responses is evaluated.
|
| ADME/Pharmacokinetics |
PCI-33380 (molecular weight 855.78, formula C₄₆H₅₂BF₂N₁₁O₃) is a fluorescent probe based on the ibrutinib scaffold. It has excitation/emission wavelengths of 532/555 nm, which are compatible with standard fluorescence detection systems. The compound is cell-permeable and can be used for live-cell imaging applications.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of PCI-33380 have been limited, as the compound is primarily used as a research tool. No significant toxicity has been reported at the concentrations used for imaging studies. The compound's safety profile supports its use as a fluorescent probe for BTK research.
|
| References |
|
| Additional Infomation |
PCI-33380 is an irreversible, selective BTK inhibitor that functions as an activity-based fluorescent probe. It was designed based on the ibrutinib scaffold and has been used to demonstrate the connection between BTK inhibitor binding and phenotypic responses. The compound is cell-permeable and suitable for live-cell imaging of BTK in cancer cells. PCI-33380 is primarily used for research purposes and has not received regulatory approval for clinical use.
|
| Molecular Formula |
C46H52BF2N11O3
|
|---|---|
| Molecular Weight |
855.800
|
| Exact Mass |
855.43
|
| Elemental Analysis |
C, 64.56; H, 6.12; B, 1.26; F, 4.44; N, 18.00; O, 5.61
|
| CAS # |
1022899-36-0
|
| Related CAS # |
1022899-36-0
|
| PubChem CID |
168008660
|
| Appearance |
Dark-red to brown-red solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
63
|
| Complexity |
1750
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
[B-]1(N2C(=CC(=C2C=C3[N+]1=C(C=C3)CCC(=O)NCCN4CCN(CC4)C/C=C/C(=O)N5CCCC(C5)N6C7=NC=NC(=C7C(=N6)C8=CC=C(C=C8)OC9=CC=CC=C9)N)C)C)(F)F
|
| InChi Key |
YUGFMNZIROEBNV-YRNVUSSQSA-N
|
| InChi Code |
InChI=1S/C46H52BF2N11O3/c1-32-28-33(2)58-40(32)29-36-15-14-35(59(36)47(58,48)49)16-19-41(61)51-20-23-56-26-24-55(25-27-56)21-7-11-42(62)57-22-6-8-37(30-57)60-46-43(45(50)52-31-53-46)44(54-60)34-12-17-39(18-13-34)63-38-9-4-3-5-10-38/h3-5,7,9-15,17-18,28-29,31,37H,6,8,16,19-27,30H2,1-2H3,(H,51,61)(H2,50,52,53)/b11-7+
|
| Chemical Name |
N-[2-[4-[(E)-4-[3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]-4-oxobut-2-enyl]piperazin-1-yl]ethyl]-3-(2,2-difluoro-10,12-dimethyl-1-aza-3-azonia-2-boranuidatricyclo[7.3.0.03,7]dodeca-3,5,7,9,11-pentaen-4-yl)propanamide
|
| Synonyms |
PCI-33380; PCI 33380; PCI33380; BMS 790052; BMS-790052; BMS790052; EBP 883; EBP-883; EBP883
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (~58.4 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.92 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.92 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1685 mL | 5.8425 mL | 11.6850 mL | |
| 5 mM | 0.2337 mL | 1.1685 mL | 2.3370 mL | |
| 10 mM | 0.1168 mL | 0.5842 mL | 1.1685 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
